Dual CAR T-cell combination a ‘promising treatment option’ for multiple myeloma

A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with relapsed or refractory multiple myeloma, according to results of a single-center, single-arm phase 2 clinical trial published in The Lancet Haematology.

The dual CAR T-cell combination resulted in a 95% response rate, with 43% of patients achieving a complete response to therapy.

“To our knowledge, this is the first study using humanized anti-CD19 CAR T cells combined with anti-BCMA CAR T cells for the treatment of relapsed or refractory multiple myeloma,” Kailin Xu, MD, PhD,professor in the department of hematology at the Affiliated Hospital of Xuzhou Medical University told Cell Therapy Next.

Read more here